Active ingredientNirogacestatCat. No. P-N072-001CAS 1290543-63-3Family · Pharmaceutical analytical standards
Nirogacestat
A selective, orally taken gamma-secretase inhibitor, approved in the United States in November 2023 as the first medicine for desmoid tumours, and in the European Union in 2025. This family brings together the active ingredient and other impurities.
Did you know?The gamma-secretase it blocks is the same molecular scissors that produces the beta-amyloid typical of Alzheimer's disease: this is why inhibitors of this enzyme have also been studied in neurology.
Go to the active ingredient →Active ingredientNirogacestatCat. No. P-N072-001CAS 1290543-63-3
ImpurityNirogacestat Impurity 1Cat. No. P-N072-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.